secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104109
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta stockholders approve 1.6M share increase to 2019 Equity Plan; re-elect directors
--------------------------------------------------------------------------------

- Stockholders re-elected Bruce L.A. Carter and Jay R. Luly as Class I directors with 20.3M and 24.7M votes for, respectively.
- Amendment to 2019 Equity Incentive Plan approved (19.5M for, 5.4M against), increasing share reserve by 1,600,000 shares.
- Advisory say-on-pay vote approved with 24.2M for, 692k against.
- Ratification of PricewaterhouseCoopers as independent auditor for fiscal 2026 approved (26.8M for, 27k against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526104109/0001193125-26-104109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526104109/enta-20260311.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer